Literature DB >> 20659860

Health technology assessment. Evaluation of biomedical innovative technologies.

Giuseppe Turchetti1, Enza Spadoni, Eliezer Elie Geisler.   

Abstract

This article describes health technology assessment (HTA) as an evaluation tool that applies systematic methods of inquiry to the generation and use of health technologies and new products. The focus of this article is on the contributions of HTA to the management of the new product development effort in the biomedical organization. Critical success factors (CSFs) are listed, and their role in assessing success is defined and explained. One of the conclusions of this article is that HTA is a powerful tool for managers in the biomedical sector, allowing them to better manage their innovation effort in their continuing struggle for competitiveness and survival.

Mesh:

Year:  2010        PMID: 20659860     DOI: 10.1109/MEMB.2010.936553

Source DB:  PubMed          Journal:  IEEE Eng Med Biol Mag        ISSN: 0739-5175


  8 in total

Review 1.  Economic evaluation of da Vinci-assisted robotic surgery: a systematic review.

Authors:  Giuseppe Turchetti; Ilaria Palla; Francesca Pierotti; Alfred Cuschieri
Journal:  Surg Endosc       Date:  2011-10-13       Impact factor: 4.584

2.  Pitfalls of prioritizing cost-effectiveness in the assessment of medical innovation.

Authors:  Christopher J D Wallis; Allan S Detsky
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

Review 3.  Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Authors:  Giuseppe Turchetti; Jinoos Yazdany; Ilaria Palla; Edward Yelin; Marta Mosca
Journal:  Clin Exp Rheumatol       Date:  2012-10-16       Impact factor: 4.473

4.  Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

Authors:  Francesca Pierotti; Ilaria Palla; Maarten Treur; Lara Pippo; Giuseppe Turchetti
Journal:  PLoS One       Date:  2015-10-21       Impact factor: 3.240

5.  Comparative health technology assessment of robotic-assisted, direct manual laparoscopic and open surgery: a prospective study.

Authors:  Giuseppe Turchetti; Francesca Pierotti; Ilaria Palla; Stefania Manetti; Cinzia Freschi; Vincenzo Ferrari; Alfred Cuschieri
Journal:  Surg Endosc       Date:  2016-06-17       Impact factor: 4.584

6.  The social cost of chronic kidney disease in Italy.

Authors:  Giuseppe Turchetti; S Bellelli; M Amato; S Bianchi; P Conti; A Cupisti; V Panichi; A Rosati; F Pizzarelli
Journal:  Eur J Health Econ       Date:  2016-10-03

Review 7.  Rare diseases under different levels of economic analysis: current activities, challenges and perspectives.

Authors:  Sara Cannizzo; Valentina Lorenzoni; Ilaria Palla; Salvatore Pirri; Leopoldo Trieste; Isotta Triulzi; Giuseppe Turchetti
Journal:  RMD Open       Date:  2018-11-12

8.  Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.

Authors:  Valentina Lorenzoni; Isotta Triulzi; Giuseppe Turchetti
Journal:  BMC Health Serv Res       Date:  2018-08-02       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.